Search the Newsroom
Filter By
News Type
Related specialties and programs
Showing 1 - 5 of 5 results
FDA Approves First Drug for Friedreich’s Ataxia
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research
The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation
In Pursuit of Cure for a Rare Degenerative Disease
A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.
Crying Over Little Things
Does your child melt down over the smallest disappointments? Help your child learn a new response.
$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence
Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.